Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial - Aptevo Therapeutics (NASDAQ